©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Glucose Stimulates the Activity of the Guanine Nucleotide-exchange Factor eIF-2B in Isolated Rat Islets of Langerhans (*)

(Received for publication, June 20, 1995; and in revised form, November 6, 1995)

Moira Gilligan (1)(§) Gavin I. Welsh (2)(¶) Andrea Flynn (2)(¶) Iwona Bujalska (1) Tricia A. Diggle (2) Richard M. Denton (2) Christopher G. Proud (2)(¶) Kevin Docherty (1)(**)

From the  (1)Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom and the (2)Department of Biochemistry, School of Medical Sciences, University of Bristol, University Walk, Bristol, BS8 1TD, United Kingdom

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Over short time periods glucose controls insulin biosynthesis predominantly through effects on preexisting mRNA. However, the mechanisms underlying the translational control of insulin synthesis are unknown. The present study was carried out to determine the effect of glucose on the activity and/or phosphorylation status of eukaryotic initiation and elongation factors in islets. Glucose was found to increase the activity of the guanine nucleotide-exchange factor eIF-2B over a rapid time course (within 15 min) and over the same range of glucose concentrations as those that stimulate insulin synthesis (3-20 mM). A nonmetabolizable analogue of glucose (mannoheptulose), which does not stimulate insulin synthesis, failed to activate eIF-2B.

The best characterized mechanism for modulating eIF-2B activity involves changes in the phosphorylation of the alpha-subunit of its substrate eIF-2. However, in islets, no change in eIF-2alpha phosphorylation was seen under conditions where eIF-2B activity was increased, implying that glucose regulates eIF-2B via an alternative pathway.

Glucose also did not affect the phosphorylation states of three other regulatory translation factors. These are the cap-binding factor eIF-4E, 4E-binding protein-1, and elongation factor eEF-2, which do not therefore seem likely to be involved in modulating the translation of the preproinsulin mRNA under these conditions.


INTRODUCTION

Glucose is the major physiological stimulus for insulin biosynthesis in pancreatic beta cells with control occurring principally at the level of translation of preformed mRNA (Permutt and Kipnis, 1972; Permutt, 1974; Itoh and Okamoto, 1980; Itoh et al., 1982; Welsh et al., 1986). The mechanism(s) by which elevated concentrations of glucose stimulate insulin biosynthesis is not known, although it is clear that the effect is exerted primarily at the level of peptide chain initiation (Permutt, 1974). The effect is selective for proinsulin synthesis, in that the stimulation of proinsulin synthesis by glucose is proportionally much greater than that of overall protein synthesis (Permutt and Kipnis, 1972).

The translational machinery in eukaryotes is highly complex and involves a number of translation initiation and elongation factors. Changes in the activities of several translation factors are believed to play roles in the regulation of translation in animal cells (Hershey, 1991; Proud, 1992; Redpath and Proud, 1994). Two factors in particular have been studied in detail.

eIF-2 mediates the binding of the initiator Met-tRNA to the 40 S subunit of the ribosome, and changes in its activity are important in regulating translation under a variety of conditions. The best characterized mechanism involves changes in the phosphorylation of its alpha-subunit at Ser-51. eIF-2(alphaP) competitively inhibits the factor (eIF-2B) which recycles eIF-2 between successive rounds of initiation (Hershey, 1991; Rowlands et al., 1988a). This recycling process involves the exchange of GDP bound to eIF-2 for GTP by eIF-2B, which regenerates active eIF-2bulletGTP. It plays an important role in the control of translation (Price and Proud, 1994) and the activity of eIF-2B is potentially subject to regulation by a variety of mechanisms including eIF-2alpha phosphorylation, allosteric control, and phosphorylation of eIF-2B on its largest () subunit. At least three protein kinases have been shown to phosphorylate this polypeptide and evidence has been presented that all three may modulate eIF-2B activity: casein kinases-1 and -2 to activate and glycogen synthase kinase-3 to inhibit (Dholakia and Wahba, 1988; Welsh and Proud, 1993; Denslow et al., 1994; Singh et al., 1994). (^1)

Phosphorylation of eIF-4E, which binds to the 5`-cap of the mRNA, correlates positively with rates of translation, and evidence has been provided that this factor plays a key role in the control of the translation of mRNAs whose 5`-untranslated regions are rich in secondary structure, which impedes mRNA translation (Hershey, 1991; Proud, 1992; Kozak, 1992). eIF-4E is now known to be regulated by an additional mechanism, involving an inhibitory protein (4E-BP1 = eIF-4E binding-protein-1), (^2)which undergoes phosphorylation in response to certain agents that stimulate translation, and, apparently as a consequence, dissociates from eIF-4E (Pause et al., 1994; Haystead et al., 1994; Lin et al., 1994). This is thought to lead to activation of eIF-4E, perhaps by allowing it to bind to other components of the ``cap-binding complex,'' which include eIF-4A, a bidirectional RNA helicase.

The elongation step of translation is also subject to regulation, in this case through the phosphorylation of elongation factor-2 (eEF-2). eEF-2 mediates the translocation step of peptide-chain elongation: phosphorylation of eEF-2 by the Ca/calmodulin-dependent eEF-2 kinase causes complete inactivation of eEF-2 (Redpath et al., 1993; Redpath and Proud, 1994).

This work was undertaken to examine the effects of elevated glucose levels on the activity and/or phosphorylation of the regulatory translation factors mentioned above. In this study we show that glucose rapidly activates eIF-2B independently of changes in the phosphorylation of eIF-2alpha, suggesting direct regulation of this factor. Glucose also does not alter the phosphorylation states of eIF-4E or eEF-2 in islets, or the association of 4E-BP1 with eIF-4E.


MATERIALS AND METHODS

Chemicals and Reagents

Chemicals and biochemicals were obtained respectively from BDH (Poole, Dorset, UK) and Sigma (Poole, Dorset, UK) unless otherwise indicated. Radiochemicals and ECL kit were purchased from Amersham International (Amersham Corp., Bucks., UK). Immobilon membrane was from Millipore (Bedford, MA), while ampholines and m^7GTP-Sepharose CL-4B were obtained from Pharmacia Biotech Inc. (Milton Keynes, UK).

Isolation of Rat Islets of Langerhans

Rat islets of Langerhans were isolated by collagenase digestion from 250-300-g male Wistar rats (Montague and Taylor, 1968), and were prepared in Gey and Gey(1936) medium using a modification of the method of Hurst and Morgan(1990). Islets were hand-picked under a dissecting microscope to purify them from exocrine tissue.

For measurement of total protein synthesis, 200 islets were preincubated in 100 µl of Hanks' balanced salt solution containing 3 or 20 mM glucose for 40 min. This medium was then removed and replaced with 100 µl of Hanks' balanced salt solution containing 150 µCi of [S]methionine. Labeling was terminated after 20 min by the addition of ice-cold Hanks' balanced salt solution. Measurement of counts incorporated into total protein was carried out essentially as described by Guest et al. (1989).

Immunoprecipitation of Insulin

Batches of 200 islets were labeled with [S]methionine as above following incubation in Hanks' solution containing 3 or 20 mM glucose for 40 min. Islets were solubilized, and proinsulin was immunoprecipitated using a modification of the method of Guest et al.(1989). Mouse 3B1 antibody was provided by Professor C. N. Hales, Department of Clinical Biochemistry, University of Cambridge, UK. Immunoprecipitates were analyzed by Tricine/SDS-PAGE followed by fluorography.

Preparation of Islet Extracts

Islets were preincubated at 37 °C in Hanks' balanced salt solution plus 3 mM glucose for the indicated times before experimentation. Groups of islets were then incubated in Hanks' medium containing the indicated glucose concentrations. Islets were then washed once in ice-cold phosphate-buffered saline solution and solubilized in buffer A: 20 mM Tris/HCl, pH 7.6, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol, 100 mM KCl, 10% (v/v) glycerol, 1% Triton X-100, 3 mM microcystin-LR, and protease inhibitors phenylmethylsulfonyl fluoride, pepstatin, and leupeptin.

Assay of eIF-2B Activity

eIF-2B activity was assayed by measuring the exchange of tritiated GDP in preformed eIF-2bullet[^3H]GDP complexes for unlabeled GTP as described elsewhere (Mehta et al., 1983; Welsh and Proud, 1992). For these experiments 1000 islets/sample were extracted in 100 µl of buffer A. Incubations (30 °C, 20 µl) contained 10 µl of cell extract, and formation of complexes was measured by the retention of residual eIF-2bullet[^3H]GDP complexes on nitrocellulose filters.

Isoelectric Focusing and Immunoblotting

Initiation factors were analyzed by one-dimensional polyacrylamide gel isoelectric focusing using a modification of a method described by Redpath(1992). Ampholines in the pH range 3.5-10 were used to study eIF-4E and eEF-2, and in the pH range 4-6.5 for eIF-2alpha. Following electrophoresis, gels were Western blotted as described elsewhere (Price et al., 1989), and proteins were visualized by enhanced chemiluminescence. Samples were prepared for isoelectric focusing analysis as follows. eIF-2 was partially purified and concentrated from cell lysates using S-Sepharose as described previously (Welsh and Proud, 1992). eIF-4E was purified by affinity chromatography on m^7GTP-Sepharose using the method described by Bu and Hagedorn(1991, 1992).

Analysis of the eIF-4E/eIF-4E-BP1 Ratio

eIF-4E was purified from cell extracts as above. The amount of eIF-4E-BP1 bound to eIF-4E was analyzed by SDS-PAGE followed by Western blotting using both anti-eIF-4E and anti-eIF-4E-BP1 antibodies. Proteins were visualized by enhanced chemiluminescence and quantified by laser densitometry on a Joyce Loebl Chromoscan 3 apparatus.

Assays for Glycogen Synthase Kinase-3 and MAP Kinase

Glycogen synthase kinase-3 was assayed after immunoprecipitation as described by Van Lint et al.(1993) and MAP kinase was measured as described in Welsh et al. (1994).


RESULTS

Effect of Glucose on Proinsulin Biosynthesis

Initial experiments were performed to demonstrate that the islet preparations were responsive to glucose. As previously demonstrated by others (Permutt and Kipnis, 1972; Guest et al., 1989) glucose elicited a marked effect on proinsulin biosynthesis as measured by the incorporation of [S]methionine into immunoprecipitable material. Islets incubated in the presence of 20 mM glucose incorporated 2-3 times as much [S]methionine into total protein as did islets incubated with 3 mM glucose (data not shown). The same conditions resulted in a 20-fold increase in incorporation into proinsulin (Fig. 1).


Figure 1: Effect of glucose on proinsulin biosynthesis in isolated rat islets of Langerhans. Rat islets of Langerhans were incubated for 20 min in medium containing 3 mM (lane 1) or 20 mM (lane 2) glucose and [S]methionine. Newly synthesized proinsulin was then immunoprecipitated and analyzed by Tricine/SDS-PAGE and fluorography. The position of molecular mass markers in kilodaltons is indicated. This result is typical of those obtained from five separate experiments.



Regulation of eIF-2B Activity in Islets

eIF-2B activity was measured after treatment of islets for periods of 0-60 min with 20 mMD-glucose. Fig. 2A shows a typical time course for eIF-2B activity with activation evident after 15 min and persisting for at least 60 min. Maximal stimulation was observed between 15 and 30 min with a decrease in activity at 60 min. Over nine entirely separate experiments the activity of eIF-2B after 30 min of treatment with 20 mM glucose averaged 318 ± 109% of the activity in extracts from cells incubated at 3 mM glucose.


Figure 2: Effect of glucose on eIF-2B activity in isolated rat islets of Langerhans. Panel A, rat islets of Langerhans incubated in medium containing 20 mMD-glucose for the indicated periods of time. The data represent the mean of three determinations of eIF-2B activity in a single experiment, where the standard errors were less than 5% for each value. This result is typical of that obtained from five separate time course experiments. Panel B, effect of various D-glucose concentrations on eIF-2B activity in isolated rat islets of Langerhans. Islets were incubated for 30 min in medium containing the indicated D-glucose concentrations. The data represent the mean of three determinations in a single experiment, where the standard errors were less than 5% for each value. This result is typical of those obtained from five separate experiments in which the maximal extent of activation ranged from 230 to 370% of the control (3 mM glucose).



The response was assessed over a range of glucose concentrations (3-20 mMD-glucose, 30 min treatment). eIF-2B activity was increased in a dose-dependent fashion (Fig. 2B). This dose response closely matches that reported elsewhere for the effects of varied glucose concentrations on insulin synthesis (Guest et al., 1989).

In a typical experiment where 20 mM glucose resulted in an increase in eIF-2B activity (282% of control where glucose was 3 mM) the hexokinase inhibitor mannoheptulose had no effect on eIF-2B activity in islets on its own (98% of control). However, when used in combination with 20 mM glucose, it suppressed the activation of of eIF-2B (151% of control). This is an accordance with the previously reported inhibition by mannoheptulose of the increase in L-type pyruvate kinase mRNA in response to glucose (Marie et al., 1993).

Phosphorylation States of eIF-2alpha, eIF-4E, and eEF-2

The best known way in which eIF-2B activity can be regulated is via changes in eIF-2alpha phosphorylation (see Proud(1992)). Since a rise in eIF-2B activity was seen here in response to glucose, a fall in eIF-2alpha phosphorylation would be one way to explain this. In four entirely separate experiments no differences in the level of phosphorylation of eIF-2alpha were detected when extracts from islets incubated in 3 mM glucose or 20 mM glucose were analyzed by one-dimensional isoelectric focusing (Fig. 3A).


Figure 3: Time courses of the effect of glucose on the phosphorylation of eIF-2alpha, eIF-4E, and eEF-2 (in isolated rat islet cells). Rat islets of Langerhans were incubated in 20 mMD-glucose for 0 (lane 1), 10 (lane 2), 20 (lane 3), 30 (land 4), and 60 min (lane 5). Cell extracts were subject one-dimensional isoelectric focusing and Immunoblotted using an anti-eIF-2alpha (Panel A), anti-eIF-4E (Panel B) antibody. Detection was by enhanced chemiluminescence. The data shown are representative of four individual experiments. Labeled arrowheads indicate the positions of the unphosphorylated and phosphorylated forms of eIF-2alpha in Panel A and of eIF-4E in Panel B.



We also analyzed the levels of phosphorylation of eIF-4E and eEF-2 in extracts from cells treated with low or high glucose concentrations. No change was seen in the ratio of unphosphorylated to phosphorylated protein following treatment with 20 mMD-glucose for eIF-4E (Fig. 3B) or eEF-2 (data not shown). For eIF-4E, densitometric analysis of blots revealed that approximately 50% of protein was in the phosphorylated form in both control and glucose-treated cells.

Association of 4E-BP1 with eIF-4E

eIF-4E was purified from cell extracts on 7-methyl GTP-Sepharose and analyzed for the presence of 4E-BP1 by SDS-PAGE followed by immunoblotting. As shown in Fig. 4, the amount of 4E-BP1 detected did not differ between extracts from cells treated with low or high glucose, when compared to the amount of eIF-4E. This indicates that glucose treatment does not cause dissociation of 4E-BP1 from eIF-4E. Species of 4E-BP1 in different states of phosphorylation can be resolved on SDS-PAGE under appropriate conditions (Diggle et al., 1995). Analysis revealed that there was no apparent change in the proportion of 4E-BP-1 in differently migrating species in response to glucose. This indicates that its state of phosphorylation was not altered in response to glucose.


Figure 4: Association of eIF-4E with 4E-BP1 in extracts from islets. Islets were incubated in 3 mMD-glucose (lane 1) or with 20 mMD-glucose for 15 (lane 2) or 30 min (lane 3), and then extracts were prepared. eIF-4E and associated proteins were isolated by affinity binding to m^7GTP-Sepharose and analyzed by SDS-PAGE followed by immunoblotting. Blots were visualized by enhanced chemiluminescence. The positions of eIF-4E and eIF-4EBP1 are marked.



Activities of Glycogen Synthase Kinase-3 and MAP Kinase

Glycogen synthase kinase-3 is implicated in the regulation of eIF-2B (Welsh and Proud, 1993). (^3)Since this work showed that raised external glucose leads to activation of eIF-2B, we measured glycogen synthase kinase-3 activity in extracts of islets incubated in the presence of different glucose concentrations. There was no discernable change in glycogen synthase kinase-3 activity in extracts of cells treated with 20 mM glucose as compared to the 3 mM glucose controls (data not shown). MAP kinase may act as an upstream regulator of glycogen synthase kinase-3 and hence, potentially, of eIF-2B (Sutherland et al., 1993; Sutherland and Cohen, 1994; Welsh et al., 1994). As for glycogen synthase kinase-3, the activity of MAP kinase was essentially unchanged on raising the external glucose concentration.


DISCUSSION

In the present study we show that the treatment of islets with glucose results in an increase in eIF-2B activity. This could account for the rise in total protein synthesis observed when islets are exposed to raised external glucose concentrations, since enhanced eIF-2B activity should result in increased supply of Met-tRNA to the ribosome and this is required for the translation of all mRNAs. Modulation of eIF-2B, and thus eIF-2 activity, is important in the overall control of translation under specific conditions such as heme deficiency in reticulocytes and in the presence of double-stranded RNA in reticulocytes and other cell types. Since the rise in in eIF-2B activity was, if anything, larger than the increase in total protein synthesis, components other than eIF-2B are presumably limiting. The rise in proinsulin synthesis is much larger than that in total protein synthesis. Lomedico and Saunders(1977) suggested that this might reflect the operation of the ``Lodish model.'' Lodish(1974) proposed, on the basis of his studies with the mRNAs for the alpha- and beta-chains of hemoglobin, that mRNAs differ in their intrinsic efficiency, such that when the activities of certain components of the translational machinery were limiting, inefficient mRNAs would be translated much less readily than efficient ones. Activation of those limiting components would, of course, lead to an overall stimulation of translation, but would allow especially marked increases in the translation of the inefficient mRNAs. Lomedico and Saunders(1977) postulated that insulin was an example of an inefficient mRNA and might be regulated in this way. Alternatively, there may be a ``directed'' mechanism operating to secure the increased translation specifically of this mRNA involving specific features of this mRNA or proteins interacting with it.

Although the activity of eIF-2B was increased, no change in the level of phosphorylation of eIF-2alpha was seen, indicating that the rise in its activity was not due, as one might have expected, to a decrease in eIF-2alpha phosphorylation. It should also be noted that the assays performed here contain a large excess of ``added'' substrate eIF-2 relative to the endogenous eIF-2 in the sample under study: under this condition effects of eIF-2(alphaP) (a competitive inhibitor) (Rowlands et al., 1988a) derived from the extract should be minimized if not eliminated, as discussed previously (Rowlands et al., 1988b; Welsh and Proud, 1992). This suggests that glucose enhances the activity of eIF-2B by mechanism distinct from eIF-2alpha phosphorylation. There are now known to be a number of situations where eIF-2B activity is altered in intact cells or tissues without any detectable change in eIF-2alpha phosphorylation (Kimball and Jefferson, 1988; Rowlands et al., 1988b; Jeffrey et al., 1990; Welsh and Proud, 1992). (^4)

In the absence of a change in eIF-2alpha phosphorylation, how can the changes in eIF-2B activity be brought about? It is likely that they involve direct regulation of eIF-2B itself, and this might in principle be a consequence of either allosteric regulation or of covalent modification. Several agents, such as nicotinamide adenine nucleotides and polyamines, modulate eIF-2B activity allosterically in vitro (Dholakia et al., 1986; Gross et al., 1988; Gross and Rubino, 1989; Oldfield and Proud, 1992; Singh et al., 1994; Kimball and Jefferson, 1995). However, it is not clear whether the concentrations of these compounds present in vivo (or changes in their concentration following cell stimulation) are in the range required to modulate eIF-2B activity. Furthermore, the assays performed in this and the other studies cited above entailed extensive dilution of the samples relative to the intracellular milieu, and these low affinity ligands are likely to be diluted out beyond the level at which they exert their allosteric effects. Another possible mechanism is the phosphorylation of eIF-2B itself. It is phosphorylated in vitro by at least three protein kinases (casein kinases-1 and -2 and glycogen synthase kinase-3), phosphorylation by each of which may modulate the exchange activity of eIF-2B (Dholakia and Wahba, 1988; Welsh and Proud, 1993; Denslow et al., 1994).^1 Phosphorylation by glycogen synthase kinase-3 appears to inhibit the activity of eIF-2B, while the other two are reported to activate. However, it is not clear whether the activities of the casein kinases are altered following glucose stimulation of islets and in our hands neither of these kinases has any measurable affect on eIF-2B activity (Oldfield and Proud, 1992). In the present work we found that glycogen synthase kinase-3 activity and the activity of MAP kinase, a potential upstream regulator of glycogen synthase kinase-3 (Sutherland et al., 1993; Cross et al., 1994; Sutherland and Cohen, 1994; Welsh et al., 1994), were not altered under conditions of elevated external glucose. Thus it is unclear how the changes in the level of eIF-2B activity are brought about.

Other translation factors are also believed to play key roles in the control of translation, especially those interacting with mRNA, which may modulate translation in a selective manner (Manzella et al., 1991; Rhoads, 1993; Sonenberg, 1993). Two such factors are eIF-4E and 4E-BP1, which are most likely to control the translation of mRNAs whose 5`-untranslated regions are rich in secondary structure. However, no changes in the phosphorylation states of either protein, or in their association with one another, were observed in these studies. They do not therefore appear likely to be important in the regulation of preproinsulin synthesis in response to glucose. Although the 5`-untranslated region of the preproinsulin mRNA does contain potential stem loops, these are relatively small (DeltaG = -8 to -13 kcal/mol depending on species; see Knight and Docherty(1992)) compared to those known to significantly influence translational efficiency (Kozak, 1989, 1991; Pelletier and Sonenberg, 1985). Thus is is unlikely that these potential secondary structure elements play a role in controlling preproinsulin synthesis, and it is thus unsurprising that eIF-4E and 4E-BP1 seem not to be involved in this process. The lack of change in the phosphorylation of eEF-2 also eliminates this protein as being involved in the glucose-induced regulation of preproinsulin translation.

In conclusion, it seems possible that the enhancement of eIF-2B activity contributes to the activation of preproinsulin mRNA translation caused by glucose although other mechanisms may also be involved. These include the proteins recently identified as binding to the 5`-untranslated region of this mRNA (Knight and Docherty, 1992). An important finding of these studies is that glucose activates the exchange factor eIF-2B independently of changes in eIF-2alpha phosphorylation.


FOOTNOTES

*
This work was supported in part by a grant from the Medical Research Council (to K. D.) and from the British Diabetic Association (Group Support) and the Wellcome Trust (Project Grant) (to C. G. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Present address: CRC Institute for Cancer Studies, Clinical Research Block, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK.

Present address: Dept. of Biosciences, University of Kent at Canterbury, CT2 7NJ, UK.

**
To whom reprint requests should be addressed: Dept. of Molecular and Cell Biology, University of Aberdeen, Marischal College, Aberdeen, AB9 1AS, UK. Fax: 44 1224 273144.

(^1)
G. I. Welsh and C. G. Proud, unpublished observations.

(^2)
The abbreviations used are: 4E-BP1, eIF-4E-binding protein-1; eEF, eukaryotic elongation factor; eIF, eukaryotic initiation factor; PAGE, polyacrylamide gel electrophoresis; MAP, mitogen-activated protein; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

(^3)
G. I. Welsh and C. G. Proud, unpublished data.

(^4)
G. I. Welsh, S. Miyamoto, C. G. Proud, and B. Safer, manuscript in preparation.


REFERENCES

  1. Bu, X., and Hagedorn, C. H. (1991) FEBS Lett. 283, 219-222 [CrossRef][Medline] [Order article via Infotrieve]
  2. Bu, X., and Hagedorn, C. H. (1992) FEBS Lett. 301, 15-18 [CrossRef][Medline] [Order article via Infotrieve]
  3. Cross, D. A. E., Alessi, D., Vandenheede, J. R., McDowell, H. S., Hundal, H. S., and Cohen, P. (1994) Biochem. J. 303, 21-26 [Medline] [Order article via Infotrieve]
  4. Denslow, N. D., Singh, L. P., and Wahba, A. J. (1994) FASEB J. 8, A1306
  5. Dholakia, J. N., and Wahba, A. J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 51-54 [Abstract]
  6. Dholakia, J. N., Mueser, T. C., Woodley, C. L., Parkhurst, L. J., and Wahba, A. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 6746-6750 [Abstract]
  7. Diggle, T. A., Bloomberg, G. B., and Denton, R. M. (1995) Biochem. J. 306, 135-139 [Medline] [Order article via Infotrieve]
  8. Gey, G. O., and Gey, M. K. (1936) Am. J. Cancer 27, 45-76
  9. Gross, M., and Rubino, M. S. (1989) J. Biol. Chem. 264, 21879-21884 [Abstract/Free Full Text]
  10. Gross, M., Rubino, M. S., and Starn, T. K. (1988) J. Biol. Chem. 263, 12486-12492 [Abstract/Free Full Text]
  11. Guest, P. C., Rhodes, C. J., and Hutton, J. C. (1989) Biochem. J. 257, 431-437 [Medline] [Order article via Infotrieve]
  12. Haystead, T. A. J., Haystead, C. M. M., Hu, C., Lin, T. A., and Lawrence, J. C. (1994) J. Biol. Chem. 269, 23185-23191 [Abstract/Free Full Text]
  13. Hershey, J. W. B. (1991) Annu. Rev. Biochem. 60, 717-755 [CrossRef][Medline] [Order article via Infotrieve]
  14. Hurst, R. D., and Morgan, N. G. (1990) J. Mol. Endocrinol. 4, 231-237 [Abstract]
  15. Itoh, N., and Okamoto, H. (1980) Nature 283, 100-102 [Medline] [Order article via Infotrieve]
  16. Itoh, N., Ohshima, T., Nose, K., and Okamoto, H. (1982) Biochem. Int. 4, 315-321
  17. Jeffrey, I. W., Kelly, F. J., Duncan, R. F., Hershey, J. W. B., and Pain, V. M. (1990) Biochimie (Paris) 72, 751-757
  18. Kimball, S. R., and Jefferson, L. S. (1988) Biochem. Biophys. Res. Commun. 156, 706-711 [Medline] [Order article via Infotrieve]
  19. Kimball, S. R., and Jefferson, L. S. (1995) Biochem. Biophys. Res. Commun. 212, 1074-1081 [CrossRef][Medline] [Order article via Infotrieve]
  20. Knight, S. W., and Docherty, K. (1992) J. Mol. Endocrinol. 8, 225-234 [Abstract]
  21. Kozak, M. (1989) Mol. Cell. Biol. 9, 5134-5142 [Medline] [Order article via Infotrieve]
  22. Kozak, M. (1991) J. Biol. Chem. 266, 19867-19870 [Free Full Text]
  23. Kozak, M. (1992) Annu. Rev. Cell Biol. 8, 197-225 [CrossRef]
  24. Lin, T.-A., Kong, X., Haystead, T. A. J., Pause, A., Belsham, G., Sonenberg, N., and Lawrence, J. C. (1994) Science 266, 635-656
  25. Lodish, H. F. (1974) Nature 251, 385-388 [Medline] [Order article via Infotrieve]
  26. LoMedico, P. T., and Saunders, G. F. (1977) Science 198, 620-622 [Medline] [Order article via Infotrieve]
  27. Manzella, J. M., Rychlik, W., Rhoads, R. E., Hershey, J. W., and Blackshear, P. J. (1991) J. Biol. Chem. 266, 2383-2389 [Abstract/Free Full Text]
  28. Marie, S., Diaz-Guerra, M. J., Miquerol, L., Kahn, A., and Iynedjian, P. B. (1993) J. Biol. Chem. 268, 23881-23890 [Abstract/Free Full Text]
  29. Mehta, H. B., Woodley, C. L., and Wahba, A. J. (1983) J. Biol. Chem. 258, 3438-3441 [Abstract/Free Full Text]
  30. Montague, W., and Taylor, K. W. (1968) Biochem. J. 109, 333-339 [Medline] [Order article via Infotrieve]
  31. Oldfield, S., and Proud, C. G. (1992) Eur. J. Biochem. 208, 73-81 [Abstract]
  32. Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., and Sonenberg, N. (1994) Nature 371, 762-767 [CrossRef][Medline] [Order article via Infotrieve]
  33. Pelletier, J., and Sonenberg, N. (1985) Cell 40, 515-526 [Medline] [Order article via Infotrieve]
  34. Permutt, M. A. (1974) J. Biol. Chem. 249, 2738-2742 [Abstract/Free Full Text]
  35. Permutt, M. A., and Kipnis, D. M. (1972) J. Biol. Chem. 247, 1194-1199 [Abstract/Free Full Text]
  36. Price, N. T., and Proud, C. G. (1994) Biochimie (Paris) 76, 748-760
  37. Price, N. T., Nakielny, S. F., Clark, S. J., and Proud, C. G. (1989) Biochim. Biophys. Acta 1008, 177-182 [Medline] [Order article via Infotrieve]
  38. Proud, C. G. (1992) Curr. Top. Cell. Regul. 32, 243-369 [Medline] [Order article via Infotrieve]
  39. Redpath, N. T. (1992) Anal. Biochem. 202, 340-343 [Medline] [Order article via Infotrieve]
  40. Redpath, N. T., and Proud, C. G. (1994) Biochim. Biophys. Acta 1220, 147-162 [Medline] [Order article via Infotrieve]
  41. Redpath, N. T., Price, N. T., Severinov, K. V., and Proud, C. G. (1993) Eur. J. Biochem. 213, 689-699 [Abstract]
  42. Rhoads, R. E. (1993) J. Biol. Chem. 268, 3017-3020 [Free Full Text]
  43. Rowlands, A, G., Panniers, R., and Henshaw, E. C. (1988a) J. Biol. Chem. 263, 5526-5533 [Abstract/Free Full Text]
  44. Rowlands, A. G., Montine, K. S., Henshaw, E. C., and Panniers, R. (1988b) Eur. J. Biochem. 175, 93-99 [Abstract]
  45. Singh, L. P., Aroor, A. R., and Wahba, A. J. (1994) Biochemistry 33, 9152-9157 [Medline] [Order article via Infotrieve]
  46. Sonenberg, N. (1993) Curr. Opin. Cell Biol. 5, 955-960 [Medline] [Order article via Infotrieve]
  47. Sutherland, C., and Cohen, P. (1994) FEBS Lett. 338, 37-42 [CrossRef][Medline] [Order article via Infotrieve]
  48. Sutherland, C., Leighton, I. A., and Cohen, P. (1993) Biochem. J. 296, 15-19 [Medline] [Order article via Infotrieve]
  49. Van Lint, J., Kandelwal, R. L., Merlevede, W., and Vandenheede, J. R. (1993) Anal. Biochem. 208, 132-137 [CrossRef][Medline] [Order article via Infotrieve]
  50. Welsh, G. I., and Proud, C. G. (1992) Biochem. J. 284, 19-23 [Medline] [Order article via Infotrieve]
  51. Welsh, G. I., and Proud, C. G. (1993) Biochem. J. 284, 625-629
  52. Welsh, G. I., Foulstone, E. J., Young, S. W., Tavaré, J. M., and Proud, C. G. (1994) Biochem. J. 303, 15-20 [Medline] [Order article via Infotrieve]
  53. Welsh, M., Scherberg, N., Gilmore, R., and Steiner, D. F. (1986) Biochem. J. 235, 459-467 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.